Lineage Cell Therapeutics (AMEX:LCTX) reported its Q4 earnings results on Thursday, March 5, 2026 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Lineage Cell Therapeutics beat estimated earnings by 108.0%, reporting an EPS of $0.004 versus an estimate of $-0.05.
Revenue was up $3.70 million from the same period last year.
Earnings History Overview
The company missed on EPS by $0.11 in the previous quarter, leading to a 1.73% increase share price change the next day.
Here's a look at Lineage Cell Therapeutics's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.02 | -0.02 | -0.03 | -0.03 |
| EPS Actual | -0.13 | -0.07 | -0.02 | -0.02 |
| Revenue Estimate | 2.43M | 1.52M | 1.72M | 1.62M |
| Revenue Actual | 3.68M | 2.77M | 1.50M | 2.90M |
To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Login to comment